STOCKHOLM–(BUSINESS WIRE)–Regulatory News: U.S. Congress has passed a new bill called The Steve Gleason Act that improves the possibility for people with communication disabilities to receive public funding of speech-generating devices (SGDs) through Medicare. President Obama’s subsequent signing of the bill is expected to take place shortly. For Tobii Dynavox, which develops and sells both eye tracking and touchscreen-based assistive technology solutions, the new bill is likely to introduce
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of today’s physicians and health care executives.One of the great frustrations experienced by physicians and other providers who participate in the Medicare program is the confusion and inconsistency of Medicare policy. While formal regulations and other guidelines such as national coverage determinations are subject to notice and comment requirements, the vast majority of Medicare policies are buried in manuals and other guidance documents, many (Read more...)
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jtc4tf/myopiapipeline) has announced the addition of the “Myopia-Pipeline Insights” report to their offering. Myopia – Pipeline Insights provides the in-depth ana…
A treat-and-extend regimen with the anti-VEGF therapy aflibercept for macular degeneration seems to be as effective as monthly therapy, according to first results from the ATLAS study. Medscape Medical News
VIENNA —The use of intravitreal bevacizumab appears to be safe in preterm infants for treatment of retinopathy of prematurity, according to a long-term multicenter study. The 9-year study performed in Mexico, Chile and India focused on systemic and adverse events, and included 418 eyes of 262 infants. Mean weight at birth was 1,338.3 grams, ranging from 600 grams to 1,800 grams. Average age at time of birth was 30 weeks, and average age at time of treatment was 36 weeks.
VIENNA The 2015 ASRS Preferences and Trends survey shows a steady increase in the use of anti-VEGFs, earlier switch of treatment for nonresponders and a growing consensus on treat-and-extend as best regimen when treating age-related macular degenerati…